FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2543642768> ?p ?o ?g. }

• W2543642768 abstract "Abstract Multiple myeloma (MM) is the result of a clonal proliferation of plasma cells. And myeloma cells have been shown to be heterogeneous with regard to their morphology and biological character. Recently, correlations between molecular subtypes and prognosis have been identified as a good prognosis with t(11;14) and a poor prognosis with t(4;14) and t(14;16) besides chromosome 13 abnormalities. But it is still unclear how those molecular events work on the prognosis of MM patients. And it is difficult to find the heterogenesity of myeloma cells in each MM case by molecular analysis. Twenty years ago Greipp et al. classified myeloma cells as mature, intermediate, immature and plasmablastic type, and then they showed that plasmablastic morphology is an independent predictor of poor survival rate after autologous stem-cell transplantation. On the other hand, Kawano et al. classified myeloma cells into three types by their phenotype (Huang N, Blood82: 3721, 1993, Kawano MM, Blood82: 564, 1993); immature (MPC1−, CD49e−, CD45−/+), intermediate (MPC1+, CD49e−, CD45−), and mature (MPC1+, CD49e+/−, CD45+). This classification according to the phenotype is good correlation with that by morphology. And they indicated that immature myeloma cells have activity of proliferation. We analyzed both phenotypic and morphological findings of myeloma (plasma) cells consecutively before and after chemotherapy in 23 MM cases in order to find what kind of drug might be useful to reduce the main population of heterogeneous myeloma cells. The phenotypic and morphological analysis were performed before and after ten-cycles of melphalan-predonine (MP) in 2 cases, three or four-cycles of vincristine-doxorubicin-dexamethasone (VAD) in 10 cases, high-dose cyclophosphamide (HD-CPA) for stem cell harvest after three or four cycles of VAD in 5 cases, high-dose melphalan followed by autologus stem-cell transplantation (HD-Mel+ASCT) in 6 cases, and administration of thalidomide at least for two months in 7 cases. First, total myeloma cells decreased after VAD, however, immature myeloma cells increased relatively (9/10). Second, HD-CPA was not effective in reducing myeloma cells furthermore after VAD (5/5). Third, HD-Mel+ ASCT could reduce immature myeloma cells clearly (4/6). In particular, a less than 5% reduction of immature myeloma cells after this course were important for the long duration of good response, but the residue of immature myeloma cells was a predictor of progressive disease (PD). Interestingly, MP was also useful to reduce immature myeloma cells (2/2). Finally, thalidomide was effective in reducing mature and intermediate myeloma cells (3/6), but not effective in immature myeloma cells. In conclusion, melphalan, if it is high-dose, has more effects on immature myeloma cells compared with those of other drugs, which might be a reason of the superiority of HD-Mel+ASCT over conventional treatment in terms of the response rate and event-free survival." @default.
• W2543642768 created "2016-11-04" @default.
• W2543642768 creator A5014250183 @default.
• W2543642768 creator A5026762883 @default.
• W2543642768 creator A5038877395 @default.
• W2543642768 creator A5060468753 @default.
• W2543642768 creator A5080018761 @default.
• W2543642768 creator A5084664308 @default.
• W2543642768 creator A5090276194 @default.
• W2543642768 creator A5091208496 @default.
• W2543642768 date "2004-11-16" @default.
• W2543642768 modified "2023-09-28" @default.
• W2543642768 title "The Reason Why High-Dose Melphalan Followed by Autologous Stem-Cell Transplantation Produces Good Response in Multiple Myeloma." @default.
• W2543642768 doi "https://doi.org/10.1182/blood.v104.11.5201.5201" @default.
• W2543642768 hasPublicationYear "2004" @default.
• W2543642768 type Work @default.
• W2543642768 sameAs 2543642768 @default.
• W2543642768 citedByCount "0" @default.
• W2543642768 crossrefType "journal-article" @default.
• W2543642768 hasAuthorship W2543642768A5014250183 @default.
• W2543642768 hasAuthorship W2543642768A5026762883 @default.
• W2543642768 hasAuthorship W2543642768A5038877395 @default.
• W2543642768 hasAuthorship W2543642768A5060468753 @default.
• W2543642768 hasAuthorship W2543642768A5080018761 @default.
• W2543642768 hasAuthorship W2543642768A5084664308 @default.
• W2543642768 hasAuthorship W2543642768A5090276194 @default.
• W2543642768 hasAuthorship W2543642768A5091208496 @default.
• W2543642768 hasConcept C126322002 @default.
• W2543642768 hasConcept C142724271 @default.
• W2543642768 hasConcept C2776364478 @default.
• W2543642768 hasConcept C2778684742 @default.
• W2543642768 hasConcept C2779050716 @default.
• W2543642768 hasConcept C28328180 @default.
• W2543642768 hasConcept C2908647359 @default.
• W2543642768 hasConcept C2911091166 @default.
• W2543642768 hasConcept C502942594 @default.
• W2543642768 hasConcept C71924100 @default.
• W2543642768 hasConcept C86803240 @default.
• W2543642768 hasConcept C95444343 @default.
• W2543642768 hasConcept C99454951 @default.
• W2543642768 hasConceptScore W2543642768C126322002 @default.
• W2543642768 hasConceptScore W2543642768C142724271 @default.
• W2543642768 hasConceptScore W2543642768C2776364478 @default.
• W2543642768 hasConceptScore W2543642768C2778684742 @default.
• W2543642768 hasConceptScore W2543642768C2779050716 @default.
• W2543642768 hasConceptScore W2543642768C28328180 @default.
• W2543642768 hasConceptScore W2543642768C2908647359 @default.
• W2543642768 hasConceptScore W2543642768C2911091166 @default.
• W2543642768 hasConceptScore W2543642768C502942594 @default.
• W2543642768 hasConceptScore W2543642768C71924100 @default.
• W2543642768 hasConceptScore W2543642768C86803240 @default.
• W2543642768 hasConceptScore W2543642768C95444343 @default.
• W2543642768 hasConceptScore W2543642768C99454951 @default.
• W2543642768 hasLocation W25436427681 @default.
• W2543642768 hasOpenAccess W2543642768 @default.
• W2543642768 hasPrimaryLocation W25436427681 @default.
• W2543642768 hasRelatedWork W1997006795 @default.
• W2543642768 hasRelatedWork W2030025176 @default.
• W2543642768 hasRelatedWork W2110863304 @default.
• W2543642768 hasRelatedWork W2142015222 @default.
• W2543642768 hasRelatedWork W2144075794 @default.
• W2543642768 hasRelatedWork W2582431155 @default.
• W2543642768 hasRelatedWork W3031522679 @default.
• W2543642768 hasRelatedWork W3031694499 @default.
• W2543642768 hasRelatedWork W4206470418 @default.
• W2543642768 hasRelatedWork W4239955546 @default.
• W2543642768 isParatext "false" @default.
• W2543642768 isRetracted "false" @default.
• W2543642768 magId "2543642768" @default.
• W2543642768 workType "article" @default.